Bevacizumab biosimilar - PolpharmaAlternative Names: bevacizumab mAb - EPIRUS; BOW 030
Latest Information Update: 01 Aug 2016
At a glance
- Originator EPIRUS Biopharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor A inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
- 16 Apr 2014 Preclinical trials in Cancer in USA (Parenteral)